Percentage of positive biopsy cores at the onset of hormone therapy for prostate cancer: prognostic significance;Pourcentage de biopsies positives chez les patients traités par hormonothérapie pour cancer de la prostate : valeur pronostique

Progres en Urologie

Volumn 19, Issue 5, 2009, Pages 321-326

  Normand, G ^a   Celhay, O ^a   Briffaux, R ^a   Pires C ^a   Dore B ^a   Irani, J ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Number of prostate biopsy cores; Percentage of positive cores; Prediction; Prostate biopsy; Prostate cancer; survival

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; GONADORELIN;

AGED; ARTICLE; BIOPSY; HUMAN; MALE; ORCHIECTOMY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; STATISTICS; TIME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 64749100892     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2008.11.004     Document Type: Article

References (15)

1. Kwak C., Jeong S.J., Park M.S., Lee E., and Lee S.E. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 168 (2002) 995-1000
2. Collette L., de Reijke T.M., Schröder F.H., and EORTC Genito-Urinary Group. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 44 (2003) 182-189
3. Briganti A., Chun F.K., Hutterer G.C., Gallina A., Shariat S.F., Salonia A., et al. Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol 52 (2007) 733-743
4. Spalding A.C., Daignault S., Sandler H.M., Shah R.B., Pan C.C., and Ray M.E. Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation. Urology 69 (2007) 936-940
5. Nurani R., Wallner K., Merrick G., Virgin J., Orio P., and True L.D. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma. J Urol 178 (2007) 1968-1973
6. Briganti A., Karakiewicz P.I., Chun F.K., Gallina A., Salonia A., Zanni G., et al. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing 13 radical prostatectomy and extended pelvic lymph node dissection. Eur Urol 51 (2007) 1573-1581
7. Sebo T.J., Cheville J.C., Riehle D.L., et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 91 (2001) 2196-2204
8. Egawa S., Suyama K., Matsumoto K., et al. Improved predictability of extracapsular extension and seminal vesicle involvement based on clinical and biopsy findings in prostate cancer in Japanese men. Urology 52 (1998) 433-440
9. Kaplan R.N., Rafii S., and Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res 66 (2006) 11089-11093
10. Van der Burg M.E., Van Lent M., Buyse M., Kobierska A., Colombo N., Favalli G., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332 (1995) 629-634
11. Clarke M., Collins R., Darby S., Davies C., Elphinstone P., Evans E., et al. Lancet 366 (2005) 2087-2106
12. Denis L.J., Carnelro de Moura J.L., Bono A., Sylvester R., Whelan P., Newling D., et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42 (1993) 119
13. Benaim E.A., Pace C.M., Lam P.M., and Roehrborn C.G. Nadir PSA as a progression to androgen independent prostate cancer. Urology 59 (2002) 73
14. Stewart A.J., Scher H.I., Chen M.H., McLeod D.G., Carroll P.R., Moul J.W., et al. Prostate specific antigen nadir and cancer specific mortality following hormonal therapy for prostate specific antigen failure. J Clin Oncol 23 (2005) 6556-6560
15. Milcent S., Lorenzato M., Enaschescu D., Enaschescu C., Birembaut P., and Staerman F. La ploïdie cellulaire : facteur prédictif de cancer de prostate localement avancé. Prog Urol 17 (2007) 819-823